Loading clinical trials...
Loading clinical trials...
A Phase 2 Trial of Emapalumab for the Prevention of CAR-T Cell Associated Toxicities
Conditions
Interventions
Emapalumab
Cyclophosphamide
+2 more
Locations
2
United States
Massachusetts General Hospital
Boston, Massachusetts, United States
Dana-Farber Cancer Institute
Boston, Massachusetts, United States
Start Date
September 18, 2024
Primary Completion Date
August 1, 2026
Completion Date
August 1, 2027
Last Updated
November 14, 2025
NCT06090539
NCT06395103
NCT05272384
NCT05139017
NCT06026319
NCT01804686
Lead Sponsor
Marcela V. Maus, M.D.,Ph.D.
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions